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Lower Urinary Tract Symptoms are common in advancing age and a major cause of disability 
through avoidance of activity and social engagement. This systematic review aimed to 
identify the most valid and reliable brief screening tool for these symptoms or bladder 
problems, to incorporate into a health promotion programme for older adults to facilitate 
discussion about self-management.   
Review eligibility criteria included studies published between 1990 and November 
2018, reporting the validity, reliability and/or acceptability of bladder health screening tools. 
Six electronic databases were searched.  
Twenty-two studies were included. Three screening tools met the criteria:  
International Prostate Symptom Score; International Consultation on Incontinence 
Questionnaire Urinary Incontinence Short-Form; Bladder Control Self-Assessment 
Questionnaire.  
Test-retest reliability for total scores of the International Prostate Symptom Score and 
International Consultation on Incontinence Questionnaire Urinary Incontinence Short-Form 
was acceptable. All three questionnaires showed evidence of acceptable levels of internal 
consistency and of convergent validity.  
Having favourable psychometric scores compared to the Bladder Control Self-
Assessment Questionnaire and for ease of use and trustworthiness of a simple questionnaire, 
the International Prostate Symptom Score and International Consultation on Incontinence 
Questionnaire Urinary Incontinence Short-Form met the criteria for recommendation for 
raising awareness and bladder health promoting interventions to reduce associated disability.  
 




Lower Urinary Tract Symptoms (LUTS) are indicators of poor bladder health. LUTS can be 
split into three categories; storage, voiding and post micturition symptoms [1]. Storage 
symptoms include frequency, nocturia, urgency, urge urinary incontinence, stress urinary 
incontinence, mixed urinary incontinence, and other urinary incontinence; voiding symptoms 
include intermittency, slow stream, straining, and terminal dribble; and post micturition 
symptoms present as incomplete emptying and post micturition dribble [2]. Therefore, an 
individual may experience LUTS alone whilst remaining continent or urinary symptoms may 
be accompanied by urinary incontinence, defined by the International Continence Society as 
“the complaint of involuntary loss of urine” [3].  
Bladder health deterioration, including neurogenic bladder dysfunction caused by 
neurological conditions, can have detrimental effects on the individual’s physical and 
psychological state [4-7].  Urinary incontinence is a disabling condition and although not life-
threatening, in older adults it can lead to skin breakdown, frailty, social exclusion, 
psychological stress, poorer quality of life, financial burden and poorer physical mobility [8-
11]. Urinary incontinence in older adults also increases the risk of falls and fractures [12,13]  
and is associated with more hospital admissions [14]. Usual daily living activities can be 
difficult or impossible as a consequence of the inability to maintain continence [15].  It has 
been reported that urinary incontinence is a major cause of independence loss [16], and is one 
of the most frequent causes for care home admissions [17] with prevalence rates as high as 
77% in nursing homes residents [18]. Many of these consequences of urinary incontinence 
have been defined as the global outcomes of disability [19] and often occur through 
avoidance of activity and social engagement as a result of urinary incontinence [20-23].    
There is a considerable prevalence of LUTS and urinary incontinence among the 
general population. Over 66 percent of women and 62 percent of men aged forty years or 
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more reported having at least one LUTS in a large scale multinational population-based 
survey study [24]. Global prevalence of urinary incontinence was estimated at 348 million 
people in 2008 and this number is expected to rise year on year [2]. Urinary incontinence 
incidence estimates for the UK, range from 1.6 to 69% in females and 2.2 to 25% in males 
[25], varying due to variations in measurement and definitions [26] and differences in 
populations [27].   
Unfortunately, urinary incontinence is often seen as part of “normal ageing”, with the 
view that nothing can be done about it, and as an embarrassing issue associated with negative 
stigma [18-32]. Only fifty percent of older adults experiencing incontinence are expected to 
seek help from healthcare practitioners [33], yet most mild urinary incontinence can be easily 
managed or cured using simple lifestyle and behavioural interventions [34,35]. Promoting 
understanding of bladder health and supporting self-management as part of a health 
promotion intervention could provide an opportunity not only to detect early bladder health 
issues, but also help prevent the progression of LUTS to urinary incontinence [36,37].   
Parsons et al. [38] examined the progression of LUTS in community-dwelling older 
men, and found that 29% who had initially presented with no or mild LUTS reported 
clinically significant LUTS two years later. More recently, research has shown that more than 
50% of middle-aged and older men experience worsening of LUTS over a 3-year period [39]. 
This highlights the importance of early screening of LUTS to recognise potential problems, to 
enable understanding and provide support for self-management of symptoms.  
Previous reviews have been conducted to establish the quality of bladder symptom 
severity assessments and/or associated quality of life [40]. However, there has been no such 
review considering the use of such tools for a general, non-clinical population of men and 
women, for the purposes of early detection and raising awareness about bladder health.  
Hence, there is a need to identify a simple, reliable, valid and acceptable method to screen for 
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LUTS and urinary incontinence which can be added to health promotion interventions to 
promote bladder health.  
The quality of a structured questionnaire and its applicability to practice are important 
considerations when selecting a potential screening tool to use in research. A questionnaire’s 
quality should be assessed by its measurement properties, usually through two specific 
psychometric concepts of reliability and validity [41]. It has also been recommended that 
health questionnaires should be brief and easy to use to be applicable to practice and to 
enhance response rates [42,43].   
The aim of the current systematic review is to identify the most psychometrically 
robust tool, for bladder health screening which is applicable to both men and women, for 
inclusion in a health promotion intervention suitable for a non-clinical population.   
Methods 
The review was developed to answer the following research questions: 
(1) Which generic bladder health screening questionnaires have been evaluated for their 
psychometric properties for use within a male and female adult population?   
(2) Which of the identified screening questionnaires are brief and easy to use (assessed as 
having ten items or less) and have a low level of missing data? 
(3) Which of the included screening questionnaires (as per question 1 and 2), have the 
best psychometric properties for use with a non-clinical adult population?  
This systematic review was built on a robust protocol, which adhered to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 




Relevant papers were identified through systematic searching of the following electronic 
databases: Medline (EBSCO SP), CINAHL (EBSCO SP), AMED (EBSCO SP), PsycInfo 
(ProQuest SP), EMBASE (OVID SP) and Web of Science (Thomson Reuters SP). Reference 
lists of included studies were also scanned to allow for literature saturation. A manual search 
was conducted in a key journal in the field (Neurourology and Urodynamics), searching 
specifically for commonly-known bladder health screening questionnaires, as advised by a 
urinary health expert, and other tools identified through the database search. PROSPERO, 
DARE and Google Scholar were searched for recently-completed reviews, to ensure no 
reviews similar to the current one had been published.  
The systematic search adopted a strategy which combined selected subject headings 
and keywords consisting of three parts: urinary bladder health (e.g. LUTS; urinary 
incontinence), screening tools (e.g. questionnaire) and psychometrics (e.g. reliability; 
validity). A limiter of ‘adults’ was applied to each search. Before the strategies were 
finalised, the search keywords were checked against each individual database’s medical 
subject headings (MESH) or thesaurus terms. The search strategy for MEDLINE is shown in 
Supplementary table 1. Some of these words/terms altered slightly, depending on the 
database being searched.   
Date limits of 1990 to November 2018 and English language limiters were applied.  
Articles assessing validity or reliability of translated versions of English language bladder 
health screening questionnaires were included.  
Inclusion Criteria 
 Peer reviewed primary quantitative research studies involving adults aged 18 years 
and over.  
 Studies that specifically report on reliability and/or validity of generic bladder health 
(LUTS and/or urinary incontinence) questionnaires.   
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 Full-text published studies written in English.   
 Studies undertaken in any type of setting/context.  
Exclusion Criteria 
 Studies of questionnaires which are specific to a particular sub-type of urinary 
incontinence or symptom constellation.  
 Studies of questionnaires only applicable to either men or women.    
 Studies of questionnaires measuring Quality of Life and not bladder symptoms.    
Study Selection Strategy 
Two review authors (LB, JB) independently screened the title and abstract data using the pre-
developed test screening questions based on eligibility, inclusion and exclusion criteria. Any 
disagreement was discussed and agreement reached, with the option of a third reviewer if 
needed. Full text reports were obtained for titles and abstracts that met the eligibility criteria 
or if there was any uncertainty. Reasons for exclusion are documented in figure 1.  
Data Extraction  
A data extraction form (Supplementary table 2) was used to collect details of the screening 
questionnaire identified, including evidence of reliability and validity for each, and 
applicability to practice measures. As definitions of different psychometric properties are 
often used interchangeably among different authors, each definition was operationalised for 
the current review (table 1). Data were extracted independently from all eligible studies by 
one reviewer (LB) and validated by a second reviewer (JB). Disagreements were resolved by 
discussion.  
[insert table 1 here] 
Quality Assessment  
In the absence of a standardised quality appraisal tool applicable to screening tools, an 
adapted appraisal checklist (from Bellet et al. [45]; Supplementary table 3) was used to assess 
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the overall methodological quality of the included studies. Bellet et al. [45] used the original 
checklist to assess the quality of articles exploring validity, reliability and responsiveness of 
objective clinical tools. The adapted checklist did not include items related to responsiveness. 
A comparison between Bellet et al’s [45] appraisal items and the adapted appraisal items, can 
be found in Supplementary table 3. The methodological quality of identified papers was 
assessed by one reviewer (LB) and validated by a second reviewer (JB). Disagreements were 
resolved by discussion.  
Bellet et al. [45] suggested a 60% positive response to the relevant checklist items 
indicated high quality whereas less than 40% response indicated poor quality. Several items 
were not applicable to all of the included studies, particularly if a standard reference had not 
been used for comparison within the study. Therefore, it was decided that these cut-off points 
would be very arbitrary and lack meaning in this review as each item would have a different 
weighting dependant on how many items were relevant to the specific study, thus providing 
an unfair comparison.  
Methods of Analysis/Synthesis: Acceptable levels 
Acceptable levels of reliability and validity scores were defined using the following criteria:   
Reliability Measures:  
 Intra-class correlation coefficient ≥ 0.70 (ICC) [46-49].  
 Kappa ≥ 0.70 [48,49].  
 Cronbach’s alpha ≥ 0.70 [46].   
 Pearson’s correlation or Spearman’s rank ≥ 0.80 [46,48,49].  
Validity Measures: 
 Correlation coefficients ≥ 0.50 [46].  
 Sensitivity ≥ 80%; Specificity ≥ 60% [46]. 
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 Receiver Operating Characteristic (ROC) curves: Area Under the Curve (AUC) ≥ 
0.80 [46].   
The practicability and acceptability of these tools were also assessed for the purpose of using 
the tool as part of a bladder health promotion programme by considering the number of items 
included in the questionnaire, time taken to complete the questionnaire, the level of missing 
data reported and the dropout/response rate reported.   
Results 
Results from Screening and Selection Process:  
Twenty-three articles were included in the review. The results of the selection and screening 
process are presented in the PRISMA flowchart (figure 1). Twenty-three articles met the 
inclusion criterion, however two of the included articles were identified as companion studies 
and were treated as one study throughout the review [50,51].  
[insert figure 1 here] 
Applicability to Practice 
Three bladder health questionnaires that fulfilled the eligibility criteria were identified: The 
International Prostate Symptom Score (IPSS)/The American Urological Association 
Symptom Index (AUASI); The International Consultation on Incontinence Questionnaire-
Urinary Incontinence Short Form (ICIQ-UI SF); and The Bladder Control Self-assessment 
Questionnaire (B-SAQ). The three questionnaires were assessed for applicability to practice 
within a community health promotion programme (table 2).   
Lower urinary tract symptoms but not urinary leakage, are screened for by the 
IPSS/AUASI, whereas urinary incontinence only is screened for by the ICIQ-UI SF. The B-
SAQ screens for LUTS and urinary incontinence. The IPSS and the B-SAQ have a total of 
eight items and the ICIQ-UI SF has four items, thus they are short to complete. The 
IPSS/AUASI has seven items that measure urinary symptom frequency and severity and 
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provides a total score indicating overall severity of LUTS experienced. The B-SAQ has four 
items that measure symptoms and urinary incontinence and four items that are related 
‘bother’ questions, all of which are included in the total score. The ICIQ-UI SF has three 
questions included in the total score, measuring frequency, amount and impact of leakage, 
with an additional unscored self-diagnosis question for type of urinary incontinence 
experienced. Scoring systems for the three identified questionnaires involve simple 
summation. The time taken to complete the questionnaire was only reported for the B-SAQ 
and was less than five minutes.  
All three questionnaires were reported to be easy to understand and results from 
several studies show a high percentage of participants being able to complete them correctly 
with low levels of missing data (table 2) [51,58,64,66-70,73,74]. However, Cam et al. [52] 
reported the IPSS to be complicated as they found that more than half of patients were unable 
to correctly complete the questionnaire in full. They identified that lower levels of education 
greatly affected how easily the questionnaire is understood. Those who reported lower 
education levels were three times more likely to be unable to complete.  This was supported 
by other studies that found high numbers of people who found the IPSS difficult to 
understand [52-54]. However, other studies have shown the IPSS to be easy to understand 
[50].  
[insert table 2 here] 
Study Characteristics 
Of the three identified screening questionnaires, the most frequently psychometrically 
assessed questionnaire was the IPSS, as demonstrated in table 3 [n = 11; 3 x AUASI 
[50,55,56]; 8 x IPSS [52,57-63], where five articles assessed the English version of the tool 
and six articles assessed other language versions including: Mandarin [59], Turkish [52], 
Spanish [61,62], Japanese [58] and Arabic [57]. Nine articles assessed the psychometric 
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properties of the ICIQ-UI SF [64-72], where five assessed the English version [64,69-71] and 
five articles explored alternative language versions including: Arabic [67], Slovene [66], 
Japanese [65], Italian [68], Chinese and Malay [64]. Only two articles were found which 
assessed the validity and reliability of the B-SAQ [73,74], both of which used English 
versions of the tool.  
The total sample inclusive of all the studies is 7901 participants (table 3), with the 
highest number of people being used to assess the IPSS (n = 4180) followed by the ICIQ-UI 
SF (n = 3221) and the B-SAQ (n = 540). Sample sizes of individual studies ranged from 57 
participants to 1620 participants with mean ages ranging from 38 years to 86 years.  The 
majority of studies used a mean sample of people in their sixties.  
Most studies (n = 11) included only men. This is not surprising as most of these 
studies (n = 9) assessed the IPSS, which was developed to screen for Benign Prostatic 
Hyperplasia (BPH). Seven studies assessed data on both men and women [58,65-
67,69,71,72]. Of these five studies, one assessed the IPSS [58] and the remaining six studies 
assessed the ICIQ-UI SF. Five of the six studies had a higher female to male ratio (60%-40%; 
84%-16%; 61%-39%; 66%-34%; 77%-23%) respectively [65-67,69,71], (the remaining study 
did not report the gender ratio [80]), whereas the only study assessing the IPSS for both sexes 
had a higher male to female ratio (54%-46%). Three studies reported data on women only 
[64,68,71]. One study did not specifically state what sex their participants were [52]. 
Although the study by Cam et al. [52] assessed the IPSS it would be inappropriate to assume 
that the sample included only males as the health status of their inclusion criteria was patients 
with lower urinary tract symptoms and not specifically BPH, therefore the sample in the 
study was considered to be men and women. No attempt was made to contact the authors of 
the Cam et al. [52] paper due to the prolonged interval since publication (more than 10 years). 
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The bladder condition reported in most cases was LUTS and/or urinary incontinence. 
Controls were often people who had no history of LUTS and/or urinary incontinence.  
Seventeen of the 22 studies were conducted in patients attending urology clinics or 
other specialist clinics. One study included a specialist sample receiving secondary care and a 
non-specialist sample receiving primary care (ICIQ-UI SF) [66], another study included only 
a non-specialist sample receiving primary care (IPSS) [58]. Gotoh et al. [65] did not state 
where their sample was recruited, or where the screening took place. The ICIQ-UI SF and the 
IPSS have both been psychometrically assessed in specialist and non-specialist health 
contexts (table 3). The B-SAQ has been assessed only in specialist contexts [73,74].   
[insert table 3 here] 
Reliability and Validity Results 
All but two articles [71, 73] assessed the reliability of the tool (table 4); test-retest reliability 
(n = 16), internal consistency (n = 14), inter-rater reliability (n = 4). Twelve studies explored 
the tool’s validity (table 5); content validity (n = 5), criterion validity (n = 3), construct 
validity (n = 11). Three of the studies which explored construct validity, actually reported 
their results as criterion validity [60,65,74]. As no objective criterion was used for 
comparison or agreement, it was decided that the results of these three studies should be 
reported as construct validity in accordance with the stated validity definitions (table 1). 
Gotoh et al. [65] claim to have assessed discriminant validity in their study, however they 
used an objective criterion (1hr pad test) hence this assessment was operationalised as 
criterion validity. Tables 4 and 5 include summaries of the reliability and validity results 
respectively, for the studies included in the current review.  
Test-retest reliability 
Of the sixteen studies that assessed test-retest reliability, seven assessed the ICIQ-UI SF, 
eight assessed the IPSS or AUASI, and one assessed the B-SAQ (table 4).  
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One study assessing test-retest reliability for the IPSS, using Pearson’s correlation, 
did not provide the statistical result [63], hence was excluded. Of the remaining seven studies 
two studies used Pearson’s correlations, reporting values of 0.81 and 0.92 respectively 
[56,60]. Four studies used the Intra-class correlation coefficient (ICC) to assess test-retest 
reliability of the IPSS total 8-item score (including 7 symptom items and 1 quality of life 
item), reporting values ranging from 0.76 to 0.93 [51,57,59,61]. One study reported the ICC 
for the 7 symptom items only which yielded a result of 0.87 [62]. Therefore, test-retest 
reliability for the total scores for the IPSS is considered acceptable as the results consistently 
evidence an ICC score ≥ 0.7 and Pearson’s correlation ≥ 0.80 [46-49].  
Of the seven studies that assessed test-retest reliability for the ICIQ-UI SF (table 4), 
four studies used Kappa coefficients, two for total score [67,69] and two for each of the three 
individual items [66,72], two used ICCs [64,68], and one used Kappa coefficient for item 1 
and 2 and ICC for item 3 and total [65]. Kappa results for total scores ranged from 0.74 to 
0.85. Kappa results for item 1 and 2 ranged from 0.61 to 0.99 and 0.62 to 0.98 respectively. 
ICC results for total scores ranged from 0.91 to 0.96. Therefore, test-retest reliability for the 
total scores for the ICIQ-UI SF is considered to be acceptable as the results evidence Kappa 
and ICC total scores ≥ 0.7 [46-49]. The test-retest reliability of individual items however is 
less consistent. Notably, the lower Kappa coefficient results for items 1 and 2 were reported 
in a study testing the validity and reliability of the Japanese version of ICIQ-SF [65].  Item 3 
was also found to have a lower than acceptable Kappa result on one study [73].  
Only one study [74] has assessed the test-retest reliability of the B-SAQ total scores 
which yielded a Kappa coefficient result of 0.60 to 0.69 (table 4), indicating an unacceptable 
level and poorer test-retest reliability than the IPSS and the ICIQ-SF. Basra et al. [74] also 
reported Lin’s coefficient of concordance ranging from 0.86 and 0.99 which indicates high 
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levels of test-retest reliability, however this measure has not been used in the assessment of 
any other tools or included studies, hence a lack of available comparability.   
The most common timescale between test and retest was 1 week (n = 7), followed by 
2 weeks (n = 4) and over 2 weeks (n = 2). Assessments of the test-retest for the ICIQ-UI SF 
used a 2-week timescale more often (n = 3) whereas the assessments for the IPSS used a 1-
week assessment more often (n = 5). The one test-retest assessment for the B-SAQ used a 4-
week timescale.  
Internal Consistency  
Of the fourteen studies that assessed internal consistency, six assessed the IPSS/AUASI, 
seven assessed the ICIQ-UI SF and one assessed the B-SAQ (table 4). The reported 
Cronbach’s Alphas for the full IPSS, ICIQ-UI SF and B-SAQ ranged from 0.75 to 0.97, 0.60 
to 0.92, and 0.91 respectively, indicating that the IPSS and the B-SAQ may have more 
desirable levels of internal consistency than the ICIQ-UI SF. Notably, the lower levels of 
internal consistency for the ICIQ-UI SF were found in only two of the seven articles [64,70].  
Excluding these findings, all three questionnaires have evidence of acceptable levels of 
internal consistency (≥ 0.7).  
Inter-rater Reliability 
Four studies assessed inter-rater reliability of the IPSS using; Pearson Correlation [63], ICC 
[56], Kappa and Spearman Correlation [55], and paired Wilcoxon tests [56], which either 
found no significant differences between physician/interviewer administered scores and self-
administered scores or significant agreement between scores (table 4). None of the included 
studies assessed inter-rater reliability for the ICIQ-UI SF or the B-SAQ. Therefore, the IPSS 
has the most evidence relating to inter-rater reliability compared to the ICIQ-UI SF and the 
B-SAQ, and that evidence suggests inter-rater reliability for the IPSS is good.  
[insert table 4 here] 
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Content Validity  
Both the ICIQ-UI SF and the B-SAQ have been assessed for face and logical content validity 
(table 5), with the conclusion that all items of both questionnaires were relevant. Some 
studies report content validity for the IPSS by measuring the levels of missing data however, 
this review takes the same stance as previous research [75] that missing data is a measure of 
acceptability rather than face or logical content validity.  
Criterion Validity  
The ICIQ-UI SF is the only questionnaire of the three identified in this review to have been 
assessed for criterion validity using an objective “gold standard” measurement (table 5). One 
study compared responses to question 6 of the ICIQ-UI SF (perceived cause of leakage) with 
urodynamic testing diagnoses which yielded an acceptable Kappa coefficient correlation of 
0.77 [66]. Another study compared the ICIQ-UI SF with a 1-hour pad test and found that 
frequency of leakage, amount of leakage and total ICIQ-UI SF scores were significantly 
correlated with the 1-hour pad test results [65]. Mary-Heck et al [71] found that the ICIQ-UI-
SF had 100 percent specificity and sensitivity when compared diagnostic results made by a 
team of health professionals. Tubaro et al. [68] however found that there was a large 
variability between the scores on the ICIQ-UI SF and the reported results from a 72-hour 
voiding diary, although specific results were not provided.   
Construct Validity: Discriminative Validity 
The ICIQ-UI SF has been found to differentiate (discriminative validity) between disparate 
groups of people including: males and females for prevalence of UI [69]; type of urinary 
incontinence [66,67], for perceived cause of urinary incontinence [69], and also between 
cases and controls for prevalence of urinary incontinence [68,69] and specifically for stress 
urinary incontinence [64]. The ICIQ-UI SF has also been shown to discriminate between 
different types of urinary incontinence in regards to the associated impact on individuals [67]. 
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Similarly, the IPSS has been shown to differentiate between cases and controls for prevalence 
of LUTS [51,57,62]. The discriminative validity of the B-SAQ has not been explored (table 
5).  
Construct Validity: Convergent/Divergent Validity 
Convergent validity for the ICIQ-UI SF has been examined in three included studies (table 
5). Significant agreement has been found between item 1 (assessing frequency of leakage) 
and item 2 (assessing amount of leakage) of the ICIQ-UI SF and the Bristol Female Lower 
Urinary Tract Symptoms (BFLUTS) questionnaire (r = 0.29, p =.002; r = 0.86, p < .001, 
respectively) [69], and the quality of life item with The Kings Health Questionnaire (KHQ; r 
= 0.72, p < .001) [69] and with item 6 of the SF-36 questionnaire (r = 0.49, p < .001) [68]. 
Item 3 (assessing impact of leakage on everyday life) has been found to have a weaker 
correlation with other questionnaires including The International Continence Society Male 
Short Form (ICSMaleSF) questionnaire and the BFLUTS (r = 0.24, p = .23; to r = 0.58, p < 
.001) [69]. The total ICIQ-UI SF scores showed significant agreement with most of the KHQ 
subscales [65].    
There is evidence of significant associations between IPSS scores and scores on 
several other questionnaires including: the Madsen-Iversen (r = 0.85) [50]; The Maine 
Medical Assessment Programme (r = 0.88) [50]; The Boyarsky (r = 0.93) [50]; The 
Psychological General Well-Being Index (PGWBI; r = 0.14 to 0.41) [50]; The EuroQol 
Visual Analogue Scale (EQ-VAS; r = -0.29) [62], and The EuroQol Five Dimensions 
Questionnaire (EQ-5D; r = -0.07 to 0.36) [62]. The convergent/divergent validity for the 
IPSS has also been examined by comparing the 7 symptom scores with item 8, the quality of 
life score (r = 0.72 and r = 0.82; table 5) [57,62] and by comparing the same categories within 
the IPSS (r > 0.33) [58] and different categories within the IPSS (r < 0.33) [58]. These 
consistent findings of significant agreements between IPSS scores and alternative 
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questionnaires and between items within the same categories of the IPSS, demonstrate that 
the IPSS displays overall good convergent/divergent validity.  
The convergent/divergent validity of the B-SAQ has been assessed by comparing the 
B-SAQ symptom scores with the KHQ symptom severity score (r = 0.46 to 0.54; table 5) 
[74]. Sahai et al. [73] also found high levels of agreement between B-SAQ individual 
symptom scores and KHQ individual symptoms in the symptom score domain (agreement 
rates: frequency 86%, urgency 85%, nocturia 84% and urinary incontinence 79%, P < 0.001). 
Comparisons have also been made between KHQ incontinence impact domain scores and the 
B-SAQ total symptom score scores (r = 0.79 to 0.81) [74] and the B-SAQ total bother scores 
(r = 0.81) [74]. These results highlight that the B-SAQ also has good convergent validity.  
[insert table 5 here] 
Critical Appraisal of Included Studies 
Differentiation regarding the quality of included studies is illustrated in table 6. Three studies 
had a positive response to all of the relevant items [58,62,66] implying high quality. Hashim 
et al. [67] has the lowest percentage of positive responses compared to the rest of the studies. 
However, two other studies [63,69] had the same amount of “No” responses as Hashim et al. 
[67], implying not that these studies were of poor quality but that they had the poorest quality 
when judged against the other included studies.  
[insert table 6 here] 
Discussion 
The current systematic review found three generic bladder health screening questionnaires 
that have been evaluated for their psychometric properties within a male and female 
population: the IPSS, the ICIQ-UI SF and the B-SAQ.  
All three of the identified questionnaires had less than ten items, with the B-SAQ 
having fewer items than both the IPSS and the ICIQ-SF. For all the questionnaires there were 
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reports of low levels of missing data and high response rates for completing the questionnaire 
on a second occasion. However, there were some differences in findings for the IPSS in 
regards to participant understanding. A possible explanation for the differences is that the 
studies which report the IPSS to be complicated were conducted in non-English speaking 
samples with non-English versions of the IPSS; Turkey, Italy, Brazil and Argentina [52-54] 
whereas Barry et al. [51] who report the IPSS easy to understand conducted their research 
using the original English version of the IPSS with English speaking patients. Simple 
summation is the scoring system used for all three questionnaires. This review therefore 
concludes that the IPSS, ICIQ-UI SF and the B-SAQ are all quick and easy to complete 
questionnaires, potentially suitable for use by adult members of the public.  
The IPSS had more validation and reliability studies and the largest sample sizes 
within studies, compared to the ICIQ-UI SF and the B-SAQ. The IPSS and the ICIQ-UI SF 
had more studies showing acceptable levels of test-retest reliability than the B-SAQ. 
However, the B-SAQ had only one assessment of test-retest reliability, which used a longer 
timescale between test and retest administrations compared to IPSS and ICIQ-SF studies. 
This may explain the differences between study findings. All three questionnaires show 
evidence of acceptable levels of internal consistency.  
Only the IPSS has evidence of acceptable inter-rater reliability. It also has evidence of 
reliability between different forms of delivery. This lack of reliability findings for the ICIQ-
UI SF and the B-SAQ does not illustrate a limitation of the tools as they were designed for 
self-completion and therefore does not devalue the psychometric strengths of these tools 
when used in the intended context.  The additional validity testing of administration mode of 
the IPSS does however provide evidence that if the IPSS was used in a health promotion 
programme, there would be the option to use either a self-administration method or 
interview-administration method, and both would be equally reliable. One study did find that 
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the ICIQ-UI SF had better test-retest reliability when paper versus paper was compared, than 
when paper versus telephone was used. If the ICIQ-UI SF or the B-SAQ was to be used, self-
administration would be required as there is a lack of evidence for acceptable levels of 
reliability associated with alternative delivery/completion methods.  
Only the ICIQ-UI SF had an assessment of validity, using a gold standard criterion. 
The reason for absence of criterion-orientated validity assessments within the realm of 
urinary bladder health may be due to the lack of agreement within the literature as to what 
constitutes a gold standard measure for LUTS and/or urinary incontinence [76,77].  
The ICIQ-UI SF and the IPSS both have good construct validity in regards to 
discriminative power however a greater variety of theoretical concepts associated with 
urinary bladder health has been explored with the ICIQ-UI SF, which focuses on urinary 
incontinence rather than LUTS, the focus of the IPSS. It is not possible to comment on the 
discriminative power of the B-SAQ as this was not assessed in the two relevant studies within 
this review.  
All three questionnaires have evidence of convergent validity. The B-SAQ has the 
least validation assessment and has been compared with only one other questionnaire; the 
KHQ. The ICIQ-UI SF and the IPSS however have been compared with several other 
questionnaires with the majority of results showing significant levels of convergence. It is 
difficult however to determine which of these two questionnaires, the ICIQ-UI SF or IPSS, 
has the better convergent validity as authors have used different questionnaires in their 
assessments, other than the quality of life questionnaires. Nevertheless, the IPSS was the only 
questionnaire that had been assessed for divergent validity, thus making the evidence for 
convergent/divergent validity stronger than the ICIQ-UI SF and the B-SAQ.  
The B-SAQ was last validated in 2014, however only two studies have validated the 
B-SAQ since its development in 2007. This lack of assessment also means that a limited 
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number of participants and types of populations have been used to test reliability and validity 
of the B-SAQ. There is less confidence therefore in the psychometric properties of the B-
SAQ than the IPSS and ICIQ-UI SF, although more validation studies for all three 
questionnaires are desirable. The acceptability of all questionnaires appears to be good as the 
majority of participants either completed the full study or completed the questionnaire on two 
occasions. A more objective assessment of acceptability, via interview or survey methods, 
has not been undertaken for any of the screening questionnaires. 
Many of the studies in the current review failed to provide adequate statistical results 
for their assessments of reliability and validity. A number of different measures of validity 
and reliability were also used making direct comparisons of psychometric properties 
impossible and it is recognised that this is a limitation of the review’s analyses. The findings 
highlight the need for global definitions of each type of validity.  
The results within this review demonstrate that the IPSS and ICIQ-UI SF are reliable 
and valid bladder health screening tools addressing different concepts; LUTS and urinary 
incontinence respectively. The UK National Health Service recognises the IPSS as a 
validated LUTS screening tool [78,79] and it has  been proposed as a standard assessment for 
the screening of LUTS worldwide [52]. The ICIQ-UI SF is the recommended screening tool 
for UI in the NICE guidelines for the management of urinary incontinence in women [80]. 
The European Association of Urology class the ICIQ-UI SF as a “Category A” questionnaire 
for measuring UI symptoms [81]. The review by Hewison et al. [40] also found the ICIQ-UI 
SF to be suitable for use by time-pressured health practitioners due to the small number of 
items, low levels of missing data, and relevance to both community and clinical settings. The 
fact that both these questionnaires are recommended screening tools and are used in daily 
clinical practice gives more confidence regarding their validity and reliability for their 
different purposes.   
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Limitations and strengths 
The applied stringent eligibility criteria may have limited the potential for identifying all 
available reliable and valid generic bladder health screening questionnaires. However, the 
objective was not only to identify screening questionnaires to assess their psychometric 
properties but also to identify those which would be applicable for use in a non-clinical 
context with the general public. Although most studies were conducted in specialist clinical 
contexts, the specific tools met the criterion that the questionnaire could be used by non-
clinical staff and respondents. By considering applicability to a non-clinical population, 
including older community living adults, the recommendation for an appropriate bladder 
health screening questionnaire to be used as part of a community health promotion 
programme, can be made with more confidence.  
The exclusion of non-English studies may be seen as a limitation however there was 
insufficient resources for translation and, given that the tools were developed in English it is 
considered unlikely that this restriction would have resulted in information relevant to UK 
practice being missed.  
Literacy levels for the understanding and comprehension of the questionnaires were 
not considered in this review. One study in the current review found that education levels 
play a significant role in the ability to complete the IPSS questionnaire correctly. This 
review’s findings also suggest that the translated versions of the IPSS may be more 
susceptible to the problems of lack of understanding than the original English versions and 
further investigation is required to confirm if linguistics is a possible contributor to poor 
understanding. It would also be useful to investigate if educational levels are independent 
influences on the understanding of the IPSS or if it is the interaction between education levels 
and the language versions of the questionnaire that has the greatest effect on this 
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understanding. Considering the evidence as it stands, health literacy should be a consideration 
when using the IPSS as part of a health promotion intervention.  
The current review did not consider the development process of the questionnaires. 
Guidelines for the development and content validity evaluation of Patient Reported Outcome 
(PRO) instruments were established in 2009 [82] which highlight that concept evaluation 
interviews with patients are considered a fundamental cornerstone of these instruments. 
Patrick et al. [83] provide a gold standard step by step methodology to developing PRO 
instruments based on the 2009 guidelines which again place a large emphasis on target 
population input into the item generation of the instrument and also documentation provision 
of the process. The International Consultation on Incontinence 2017 guidelines also state [84, 
p.549] 
In addition to clinician input and literature review, questionnaire items must be 
generated from a patient perspective and include patient views. This is obtained 
through focus groups or one-to-one interviews … 
 Barry et al. [50] developed the AUASI (IPSS) before these guidelines were produced 
and this fundamental stage (concept elicitation) was not considered, stressing an important 
limitation of the IPSS. Nevertheless, the 2009 guidelines [83] suggest that existing 
questionnaires that did not consider this concept elicitation stage, may still be classed as 
being of good quality as long as trials have shown the questionnaire to have good levels of 
reliability. The current review found the IPSS to have good levels of reliability, widespread 
use and acceptance, which can be used as indicators of its acceptability.  
The findings highlight that most of the psychometric assessments of the three 
identified questionnaires have been undertaken with people who have already identified they 
have LUTS and/or urinary incontinence and have sought healthcare. If these questionnaires 
are to be used for general screening and raising awareness of LUTS and/or urinary 
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incontinence amongst the general public, it is advisable that more psychometric assessments 
are conducted in non-clinical contexts.  
Conclusion 
The current review has highlighted that there are very few reliable and valid generic bladder 
health screening tools available. The reliability and validity of the IPSS and the ICIQ-UI SF 
have been more rigorously tested than the B-SAQ. Furthermore, the IPSS has stronger 
evidence for inter-rater reliability and convergent/divergent validity than the ICIQ-UI SF 
however they screen for different conditions. The ICIQ-UI SF only screens for UI and does 
not capture non-leakage urinary symptoms, meaning that potential opportunities could be lost 
to prevent the progression of urinary symptoms to urinary incontinence [2].  The IPSS 
provides assessment of storage and voiding LUTS without the screening of urinary 
incontinence. However urinary incontinence is a major contributor to avoidance of activity 
and social engagement in older adults [20-23], and is potentially amenable to supported self-
management and bladder health promotion interventions. The B-SAQ covers both LUTS and 
urinary incontinence but focuses on certain type of LUTS (storage) which results in missed 
detection of important voiding symptoms.  
In summary, the IPSS and the ICIQ-UI SF are generic bladder health screening 
questionnaires that have been evaluated for their psychometric properties within male and 
female adult populations in specialist and generic public health contexts. They are brief, easy 
and fast to complete, use simple scoring systems and are associated with low levels of 
missing data. They have both been subjected to the most rigorous psychometric testing in 
comparison to the B-SAQ. It is suggested that the IPSS be used when screening for LUTS 
and the ICIQ-UI SF be used when screening specifically for urinary incontinence. Both 
questionnaires are recommended as good options for screening for bladder health in a 
24 
 
community health promotion programme to tackle disability outcomes associated with 
LUTS.   
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Test-retest reliability refers to the likelihood of the same instrument obtaining 
similar/stable results when administered to the same group of heterogeneous subjects at 
different time-points [44].  
When assessing test-retest reliability it is important to consider the timescales between 
the different tests/administrations as variables are likely to change over time. If the 
timescale is too long, the changes within variables will affect the results of the reliability 
assessment. Alternatively, enough time must be provided to eliminate/reduce the 
possibility of practice effects, which could exaggerate the agreement found between 




Internal consistency reliability refers to the homogeneity of the instrument (that is, the 
degree of interrelatedness among items), whereby responses to items measuring the 
same variable should yield similar or consistent results from only one time-point, 
indicating good reliability [46]. Internal consistency may measure the level of 
association between each item (Cronbach’s Alpha) or the correlation between one half 
of an individual’s responses with the other half of the same person’s responses (split 




Inter-rater reliability assessment compares the level of agreement between two or more 




Content validity may include either logical validity or face validity tests. Logical 
validity refers to the considered opinion of expert judges as to the extent to which the 
items of a questionnaire comprehensively represent the concept of interest [47,49]. Face 
validity is the extent to which a questionnaire is perceived as covering the concept it 
aims to measure. Content validity which is not quantified by statistics is a subjective 
type of validity, therefore being a less sophisticated form of validity than criterion-
oriented validity and construct validity, which are objective forms of validity [50]. 
However, testing for content validity is still important for making an assessment of the 




Criterion-orientated validity is a measure of how well one instrument compares with 
another instrument or predictor, called a criterion. Concurrent and predictive validity are 








Concurrent validity is determined by assessing the correlation between the questionnaire 
and another, more objective measure of the same domain, often acknowledged as the 
gold standard method, when administered simultaneously [40,45,46]. An example of a 
“gold standard” criterion for assessing UI is urodynamic testing [51].  
 
Predictive validity is assessed by measuring the correlation of an instrument with a gold 
standard criterion that will be available in the future [54].  
 
Construct Validity Construct validity which includes discriminative, convergent and divergent 
(discriminant) validity [46] is a theoretical measure of how meaningful (truthful) a scale 






Discriminative validity is the measurement of an instrument’s ability to discriminate 




Convergent validity is the degree to which the scores of one instrument relates to scores 
of another instrument which is expected to be a measure of the same realm [40,52]. In 







Divergent (discriminant) validity is the degree to which the scores of one instrument’s 
scores do not correlate with scores of another instrument which measures disparate 


























table 2:   Screening Questionnaire Characteristics 






Scoring system Time taken 
to complete 
Missing data Dropout/response 
rate 




The ICIQ-UI Short Form comprises four items, three of which are scored and 
summed to yield the total score (score 0–21). These questions assess the 
frequency of leakage (score 0–5), the amount of leakage (score 0–6), and the 
impact of incontinence on the quality of life (score 0–10). The fourth 
unscored question is self-diagnostic about the perceived causes of 
incontinence. The higher the score the greater the severity. (Avery, 2004; 
Hashim 2006; Rotar 2009; Gotoh, 2009; Tubaro, 2006; Lim, 2017, Kurzawa, 
2018; Mary-Heck, 2018; Uren, 2017).  
 
 Levels of missing 
data; (mean 1.6%  
range, <1% to 2%: 
Avery, 2004); (<1%) 
for all items: Hashim 
2006; (<1%): Lim, 
2017.  
 
89% of participants 
completed all items. 
(Avery, 2004) 
 
1 question unanswered 
by 1 person at T1 but 
was answered at T2 
(Rotar, 2009) 
 
Missing responses to 




Lowest response rate = 60%, 
highest response rate = 96%. 
(Avery, 2004).  
 
 
B-SAQ LUTS and UI 8 items (Basra, 
2007). [74] 
The B-SAQ comprises eight items, four items assess symptoms and four 
assess bother. Individual symptom and bother scores are summated to give an 
overall symptom and bother score. A score interpretation table grades the 
severity of symptoms and bother.  
 
The questionnaire recommends seeking medical attention if the symptom 
score is ≥4 and states that the patient may benefit from help if the bother score 
is ≥1. A separate statement in bold at the bottom of the questionnaire 
specifically identifies “red flags” and warns that those patients with 
haematuria, voiding difficulty or pain on passing urine should consult their 
doctor immediately. (Basra, 2007; Sahai, 2014). 
 







in <5 min. 
(Sahai, 2014; 
Basra, 2007).  
A total of 98% (Sahai, 
2014); 89% (Basra, 
2007) of participants 
completed all items 
correctly (Sahai, 2014; 
Basra, 2007). 
 
89% correctly completed and 












The IPSS comprises seven items that measure symptom frequency and 
severity, each of which is rated from 0 (not at all) to 5 (almost always), plus 
one disease specific quality of life question. The total score is the sum of 
items 1–7 (range: 0–35) according to the severity of symptoms. (Quek 2005). 
Symptoms are considered mild for scores between 0 and 7, moderate for 
 Questions were clear 
to 95% of participants. 
(Barry 1992b).  
 
72% understood all 
87% of participants returned 
questionnaire at time 2. 
(Barry 1992b).  
  





scores between 8 and 19, and severe for scores between 20 and 35. (Badia, 
1998; Johnson, 2009).  
 
AUASI questions  
(Johnson, 2009).  
 
54% of patients were 
unable to complete the 
IPSS in full for lack of 
understanding Most of 
these patients (49%) 










89% completed all 
questions. Missing 
responses to individual 
items ≤7.5%. 
(Okamura 2009).  
the questionnaires. 
(O’Connor, 2003).  
 
91% of participants 
completed the full study. 
(Johnson, 2009).  
 
97.6% of patients attended 
visit 2 (Garcia-Losa, 2001).  
 
96% of patients attended for 
follow-up (Hammad, 2010).  
ICIQ-UI SF = International Consultation on Incontinence, Urinary Incontinence Short Form; IPSS = International Prostate Symptom Score; B-SAQ – Bladder Control Self-Assessment Questionnaire; 


























table 3:   Study Characteristics 
 










Age Gender Health status Context of 
Screening 
Avery, 2004 [69] ICIQ-UI SF/ English 1306 (from all 
studies) 469, 
223, 246, 57, 
206, 105. (used 
6 samples as 
had multiple 
studies) 
SA  Mean age (from all 
studies) ranged 
from 50.1 years to 
66.6 years.  
Both - 800 females/ 
506 males in total.  
 
Female to male ratio 
= (61% - 39%) 
Differing levels of urinary 
symptoms. No more information 
provided.  
Community-based samples 
and urology clinic 
attendees used. Specialist 
services – clinicians.  





SA  Mean age 47 years 
(Range 18-83 
years).  
All female.  All women were attending a 
general gynaecology or 
urogynaecology clinic. Clinical 
diagnosis from the doctors’ 
evaluation sheet defined 31% of 
participants were asymptomatic 
controls.  
Screening took place 




Specialist Services – 
clinicians.  
Sahai, 2014 [73] B-SAQ/ English 211 SA  Cases mean age 62 
years, controls 
mean age 41 years.  
All male.  Male patients attending a busy 
urology or dedicated stone 
outpatient clinic. Cases 
confirmed by Urologist if LUTS 
was present in a consultation.  
Took place at outpatient 
urology clinic. Specialist 
services.  
Barry, 1992(a) [50] AUA SI/ English 135 SA Not provided. But 
control group were 
aged between 18 
and 55 years. 
Details provided in 
Barry 1992 b – see 
below.  
All male. 76 men with clinically defined 
BPH, 59 men being evaluated for 
non-urological complaints but 
with no history of urinary or 
prostate problems.  
3 urology practices. 
Specialist services.  
Barry 1992(b) [51] AUA SI/ English 318 (210 BPH 
patients and 108 
controls.) 
SA  1st validation study 
BPH patients mean 
age = 64 ± 9 years, 
range 44 to 82 
years, control 
subjects mean age 
39 ± 9 years, range 
21 to 55 years).  
 
2nd validation study 
All male. Men with BPH and controls 
without.  




= 107 BPH patients 
and 49 controls. 
Age distribution 
almost identical to 
1st validation study.  
 
Final phase of 
validation mean age 
is 66 years.  
Barry, 1995 [56] AUA SI/ English 124  
 
SA versus physician 
administration 
Group 1 mean age 
= 68.7 (sd 10.2), 
Group 2 mean age 
= 68.7 (SD 7.5) 
group 3 mean age = 
67.4 (SD 7.8). 
All male. 41 visually impaired or illiterate 
men and 83 able men. All had 
history of symptomatic BPH.  
Screening took place at 10 
specialist clinical 
practices.   
O’Connor, 2003 [60] IPSS/ English 210 SA Mean age = 67 
years (range 41-94). 
All male.  Men with LUTS who were either 
on a stable medical regimen to 
treat their symptoms or were 
receiving no therapy.  
Screening took place in 
urologist office. Specialist 
services.  
Johnson, 2009 [55] AUA SI/ English 407 SA and interview 
Administration. 
Mean age = 59.13 
years.SD = 13.89.  
Males (although not 
stated) 
Consecutive patients from the 
urology clinics.   
Took place in urology 
clinics. Specialist services.  
El Din, 1996 [63] IPSS/ English 71 SA at time 1. SA and 
physician 
administration at time 
2. 
Mean age = 63 
years (sd = +-9) 
range = 44 to 83 
years. 
All male.  Men with BPH and/or LUTS 
who had been referred to a 
prostate centre. 
Prostate centres. Specialist 
services – physician.  
Cam, 2004 [52] IPSS/ Turkish 150 SA versus physician 
administration.  
58±8 y (range 
50–79 y) 
Not stated Patients who had been admitted 
to an outpatient department due 
to lower urinary tract symptoms 
were recruited.  
Outpatient urology clinic. 
Specialist services.  
Garcia-Losa, 2001 
[61] 
IPSS/ Spanish 946 SA versus interview 
administration.  
Mean age 65.57 
(7.80). 
Males (does not state 
this but inclusion 
criteria were patients 
with BPH).  
Patients over 50 years of age 
diagnosed as having BPH 
according to clinical criteria, 
with any duration of disease 
evolution and severity, were 
recruited consecutively.  
Clinicians rated health status 
related to BPH as good or quite 
good in 52% of the patients in 
the sample as a whole. 
52 urology clinics 
throughout Spain. 
Specialist services.  
Okamura, 2009 [58] IPSS/Japanese 1620 SA Sample A women 
mean age 70.1 ± 
8.4, Sample A men 
mean age 71.1 ± 
9.1. Sample B 
women mean age 
67.5 _±9.1. Sample 
B men mean age 
66.7 ± 8.5. 
Both - 746 women, 
874 men. Female to 
male ratio = 46% - 
54%).  
(sample A) was collected from 
outpatients consulting hospital 
doctors and the other (sample B) 
was from outpatients consulting 
general practitioners for various 
chronic medical problems.  
Consulting hospital doctor 
or consulting a general 
practitioner. Non-specialist 
services but not 




Rotar 2009 [66] ICIQ-UI-SF/ Slovene 120 plus 70 plus 
69 plus 54. 
(313) 
SA Validation process 
– baseline – 120 
participants, 40% 












men, mean age 60 
years (±13). 
Both. – Male to 
female ratio % = 
study 1 40:60. Study 
2 40:60. Study 3 
41:59. Study 4 6:94. 
 
Inclusive male to 
female ratio = 40% - 
60%.  
The baseline sample of patients 
was composed of patients with 
LUTS who attended urology or 
gynaecology outpatient clinics 
and elderly institutionalized 
patients. All the participants had 
satisfactory cognitive function. 
Stability was tested in a group of 
70 patients that consisted of 
urology or gynaecology 
outpatient clinic attendants and 
elderly institutionalized with 
various levels of LUTS.  
 
Included urology and 
gynaecology outpatient 
clinic attendees, elderly 
institutionalized patients 
and a community sample. 
Specialist services and 
non-specialist services.  
Badia, 1998 [62] IPSS/ Spanish version 127 (59 patients 
and 68 
controls).  
SA Patients mean age 
65.8 years ± 8.3. 
Controls mean age 
36.8 years ± 10.2. 
Males (although not 
stated but recruited 
patients with BPH).  
78% of patients had moderate or 
severe urinary symptoms. 
Exclusion criteria for controls 
was any current or past clinical 
diagnosis related to urinary 
problems or BPH, or history of 
renal, vesical, or other chronic 
urinary disease. 
Screening took place in 6 
urologic clinics. Patients 
with BPH and control 
subjects without BPH. 
Specialist services – 
clinicians.  
Gotoh, 2009 [65] ICIQ-UI SF/ Japanese 
version 
122 patients 
(Study 1)  
SA median age: 62 
years; range: 53–70 
years 
Both - female patients 
comprised 83.6% of 
the study group. 
All participants had UI.  Not stated where 
participants were recruited 
from.  
Hammad 2010 [57] IPSS/ Arabic version 139 men (76 
patients and 63 
normal subjects) 
SA Mean age control 
group 32.6 years 
(8.1). Mean age 
patients 61.4 years 
(9.1). 
All Male.  76 patients with urinary 
symptoms due to BPH and in 63 
control subjects without BPH; 25 
patients had transurethral 
resection of prostate (TURP) 
whereas the remaining 51 
patients were treated with 
terazosin. 
Took place at urology 
clinic visit. Specialist 
services.  
Quek, 2005 [59] IPSS/ Mandarin version 68 participants 
(39 BPH group, 
29 Control 
group).  
SA  BPH group (n = 39; 
mean age: 70.64 ± 
8.51 years), control 
group (n = 29; 
mean age: 63.37 ± 
12.96 years). 
All Male.  Patient group reported BPH. 
Control group were patients with 
renal stones. 
Recruited from urology 
clinic and ward. Specialist 
services.  
Tubaro 2006 [68] ICIQ-UI SF/ Italian 103 
participants.  
SA Cases and controls 
were enrolled in 
homogeneous age 
classes (≤ 50 or > 
50 years). (44 ≤ 50 
years, 45 > 50 
All females Cases:  female patients who had 
been having LUTS for ≥ 3 
months. Controls: healthy 
women who had had no LUTS 
for ≥ 3 months.  
 
Took place in 4 Italian 





Hashim, 2006 [67] ICIQ-UI SF/ Arabic For validity 
testing = 131 
participants. For 
reliability 
testing = 102 of 
the  participants 
Not stated For validity testing 
= 131 participants – 
44 male 87 female, 
mean age 37.8, 
range 18-73 years. 
For reliability 
testing = 102 
participants – 34 
male 68 female, 
mean age 37.7 
years, range 17-73 
years). 
Both - Validity 
testing 34% male. 
Reliability testing 
33% male.  
Patients attending urology clinics 
with varying levels of UI.   
Urology outpatient clinics. 
Specialist services.  
Lim, 2017 [64] ICIQ-UI SF/ English, 
Malay and Chinese 
248 participants 




SA Participants with 
Stress UI Mean age 
52.2 ± 8.61 years. 
(Range 31 – 78 
years). Control 
group Mean age 
45.7 ± 9.59 years. 
(Range 23 – 66 
years) 
All female.  Cases: Female patients diagnosed 
with Stress UI. Control group: 
female volunteers who were 
continent.  
Urology outpatient clinic 
in Malaysia. Specialist 
services.  








SA Mean age 68.86 ± 
8.71 years.  
All male.  Participants with moderate to 
high symptom burden. Only 
patients undergoing initial 
treatment for SUI were 
contacted. Pre-operative patients. 
Urology outpatient clinic 
in Canada. Specialist 
services.  






Nurse Mean age = 86.2 ± 
6.5 years.  
76.5% female.  Vulnerable,  elderly  patients (at 
least 75 years old) with at least 1 
geriatric syndrome and with 
spontaneous micturition.  
Acute Care for Elders 
(ACE) unit of hospital in 
Switzerland. 
Uren, 2017 [72] 
 
 





SA vs Telephone 
administration.  
Not stated.  Males and females. 
Ratio not stated.  
Patients attending urology clinics 
with complaints of LUTS.    
Urology outpatient clinic 
in England. Specialist 
services. 
Key: B-SAQ = Bladder Control Self-Assessment Questionnaire; AUA SI = American Urological Association Symptom Index; IPSS = International Prostate Symptom Score; SA = self-administration; 
ICIQ-UI SF = International Consultation on Incontinence-Urinary Incontinence Short Form; UI = urinary incontinence; LUTS = Lower Urinary Tract Symptoms; BPH = benign prostatic hyperplasia; 





















Lim, 2017 [64] ICIQ-UI SF 1 week ICC = 0.95 (English 
version) 
ICC = 0.91 
(Chinese version) 
ICC = 0.96 (Malay 
version) 
 
NR Cα = 0.60 (English 
version) 
Cα = 0.61 (Chinese 
version) 
Cα = 0.76 (Malay 
version) 
Avery 2004 [69] ICIQ-UI SF 2 weeks k = 0.74 (p<0.001) 
 
NR Cα = 0.92 
Gotoh, 2009 [65] ICIQ-UI SF 
 
2 weeks k = 0.61 for item 1  
k = 0.62 for item 2  
ICC = 0.90 for item 
3 
ICC = 0.91 for total 
score 
 
NR Cα = 0.78 
Hashim, 2006 [67] ICIQ-UI SF 2 weeks k = 0.85 (p< 
0.0001) 
NR Cα = 0.71 
 
Rotar, 2009 [66] ICIQ-UI SF 2 weeks k = 0.99 for item 1 
k = 0.98 for item 2 
k = 0.95 for item 3 
 
NR Cα = 0.81 
 
Kurzawa, 2018 [70] 
 
ICIQ-UI SF NR 
 
NR NR Cα = 0.63 for all 3 
items.  
Cα = 0.67 with 
deletion of 3rd item.  
 
Uren, 2017 [72] 
 
ICIQ-UI SF Paper: 20 minutes 
Telephone: 1 week 
 
Paper vs paper: 
k = 0.74 for item 1 
k = 0.88 for item 2 
k = 0.52 for item 3 
Paper vs Telephone: 
k = 0.62 for item 1 
k = 0.75 for item 2 




Tubaro, 2006 [68] ICIQ-UI SF 1 week ICC = 0.93 NR Cα = 0.90 
 
Barry 1992 [50] AUA SI 1 week r = 0.92  NR Cα = 0.86 
 






raters. p = 0.48 
Cα = 0.75 to 0.87 
(range between time 
and group).  
El Din, 1996 [63] IPSS 8 weeks r = 0.63  
 
r = 0.77 NR 
Garcia-Losa, 2001 
[61] 
IPSS 4 weeks ICC = 0.76 
 
NR NR 
Badia, 1998 [62] IPSS 1 week ICC = 0.87 (without 
item 8) 
r = 0.92  
 
NR Cα = 0.81 





Hammad, 2010 [57] IPSS 1-2 weeks ICC = 0.88 NR Cα = 0.85 
 
Johnson, 2009 [55] AUA SI NR NR r = 0.75 (rho) 
 










Okamura, 2009 [58] IPSS NR NR NR Cα = 0.80 (women) 
Cα = 0.74, 0.79 
(range between 
groups of men). 
 
Quek, 2005 [59] IPSS 1 week ICC = >0.93 NR Cα = 0.97 
 
Basra, 2007 [74] B-SAQ 4 weeks k = 0.60 to 0.69 NR Cα = 0.91 
 
ICIQ-UI SF = International Consultation on Incontinence, Urinary Incontinence Short Form; IPSS = International Prostate 
Symptom Score; AUASI American Urological Association Symptom Index; B-SAQ – Bladder Control Self-Assessment 
Questionnaire; k = kappa; ICC = Intra-class Correlation Coefficient; r = correlation coefficient (Pearson product-moment 





table 5:  Validity Results for Included Studies 
 













ICIQ-UI SF Clinical experts and 
participants all agreed 
that all 3 versions of 
the ICIQ-UI SF 
(English, Chinese and 
Malay) were 
intelligible and 
covered all important 
domains.  
NR NR Could discriminate between 
women with Stress UI and healthy 
continent controls (p < 0.001).  
 
ROC = 1.00 for all three versions 




ICIQ-UI SF Interviews with UK 
urology clinic 
attendees and reviews 
by clinical and social 
science experts 
indicated that items in 
the ICIQ were well 
interpreted and 
covered all important 
domains. 
NR NR Could discriminate between men 
and women (p < 0.001) and 
between community and urology 





r = 0.29 to 0.86 (rho) (agreement 
between responses to ICIQ-UI SF and 
BFLUTS items).  
 
r = 0.24 to 0.58 (rho) (agreement 
between responses to ICIQ-UI SF and 
BFLUTS/ICSMaleSF items, assessing 
perceived causes of incontinence).  
 
r = 0.72 (agreement between ICIQ-UI 




KHQ for assessing 
convergent validity.  
Gotoh, 2009 
[65] 
ICIQ-UI SF NR Linear trends found 
between clinical 
severity measures 
(including 1-hr pad 
test and n of daily 
incontinence 
episodes) and ICIQ-
SF scores.  
NR NR r = 0.74 (rho) (agreement between 
ICIQ-UI SF scores and severity 
measure subscale of the KHQ). 
 
r = 0.68 (rho) (agreement between 
ICIQ-UI SF scores and; incontinence 
impact subscale of the KHQ; 
limitations in functional ability 
subscale of the KHQ; physical 
limitations subscale of the KHQ). 
  
r = 0.59 (rho) (agreement between 
ICIQ-UI SF scores and social 
limitations subscale of the KHQ).  
 
r = 0.55 (rho) (agreement between 












ICIQ-UI SF scores and emotions 






ICIQ-UI SF NR NR NR Could discriminate between the 
types of incontinence reported by 
males and females 
 
χ² = 35.4, p< 0.0001 
 
Could discriminate between 
individuals with mixed UI and 
those either with urge UI or stress 







ICIQ-UI SF NR k = 0.77 (agreement 
between responses 
to Q6 of ICIQ-SF 
and urodynamic test 
results).  
 
NR Could discriminate between types 
of UI reported by men and 
women. Significant differences 




NR Urodynamic testing 
for assessing 




ICIQ-UI SF NR Se, and Sp were 
100% when 
compared to a 
reference measure 
which was a team of 
health experts who 
made diagnostic 
decisions .   
 
NR NR NR NR 
Tubaro, 2006 
[68] 
ICIQ-UI SF NR Large variability 
between ICIQ-UI SF 
scores and reported 
results from a 72-
hour voiding diary, 
although specific 
results were not 
provided.   
 
NR Could discriminate between cases 
and controls. 
 
Used a Wilcoxon two-sample test. 
P < 0.001. 
 
r = 0.485 (rho) (agreement between 
ICIQ-UI SF item on QOL and item 6 
of the SF-36). 
 
SF-36 for assessing 
convergent validity.  
Barry, 1992 
[50] 
IPSS NR NR NR Could discriminate between BPH 
patients and control patients. 
 
ROC = 0.82 to 0.94. 
 
 
r = 0.85 (agreement between IPSS and 
Madsen-Iversen). 
 


















IPSS NR NR NR Could discriminate between BPH 
patients and control patients. 
 
ROC = 0.95 (whole instrument) 
 
ROC = 0.79 to 0.88 (individual 
IPSS Sp items). 
r = -0.07 to 0.36 (rho) (agreement 
between IPSS Sp and EQ 
dimensions). 
 
r = -0.29 (rho) (agreement between 
IPSS Sp and EQ visual analogue 
scale). 
 
r = 0.14 to 0.72 (rho) (agreement 
between IPSS SP and PGWBI 
dimensions). 
 
r = 0.72 (rho) (agreement between 
IPSS Sp and item 8 of the IPSS). 
 
EQ-5D, EQ-VAS, 







IPSS NR NR NR Could discriminate between BPH 
patients and control patients. 
 
ROC = 0.93 
 
ROC = 0.79 to 0.90 (individual 
IPSS items). 
 
r = 0.82 (rho) (agreement between 






IPSS NR NR NR NR r > 0.33 (rho) (agreement between 
most voiding items and most storage 
items on IPSS). 
 
r ≤ 0.33 (rho) (agreement between 
different categories, i.e. voiding with 





B-SAQ The B-SAQ was 
developed by a 
European panel of 
experts in LUTD. 
Opinions from the 
expert panel and focus 
group interviews with 
patients concluded that 
the B-SAQ items were 
relevant. 
 
NR NR NR r = 0.46 to 0.54 (agreement between 
B-SAQ symptom scores and symptom 
severity scale of the KHQ) 
 
r = 0.79 (agreement between B-SAQ 
symptom scores and the incontinence 
impact domain of the KHQ). 
 
r = 0.81 (agreement between B-SAQ 
bother scores and the incontinence 
impact domain of the KHQ). 
 
k = 0.62 to 0.71 (agreement between 
individual items of the B-SAQ and 
individual items of the symptom 
KHQ for assessing 
convergent validity.  
44 
 
severity scale of the KHQ). 
 
k = 0.52 (agreement between overall 




B-SAQ NR NR NR NR r = 0.94 (agreement between B-SAQ 
symptom scores and B-SAQ bother 
scores). 
 
r = 0.86 (agreement between B-SAQ 
frequency symptom scores and 
individual symptoms in the symptom 
score domain of the KHQ) 
 
r = 0.85 (agreement between B-SAQ 
nocturia symptom scores and 
individual symptoms in the symptom 
score domain of the KHQ). 
 
KHQ for assessing 
convergent validity. 
ICIQ-UI SF = International Consultation on Incontinence, Urinary Incontinence Short Form; IPSS = International Prostate Symptom Score; B-SAQ – Bladder Control Self-Assessment Questionnaire; k = 
kappa; r = correlation coefficient (Pearson product-moment correlation unless specified otherwise; ROC = areas under their receiver operating characteristic curves; χ² = Chi square; NR = not reported; * 
1 = Chi square test results not provided; *2 = Correlation for total scores for ICIQ-UI SF and KHQ not provided; KHQ = Kings Health Questionnaire; BFLUTS = British Female Lower Urinary Tract 
Symptoms questionnaire; ICSMaleSF = The International Continence Society Male Questionnaire Short Form; SF-36 = 36-Item Short Form Survey Instrument; MMAP = Maine Medical Assessment 















Table 6:   Critical Appraisal of Included Studies 
 






























Y NA NA NA N NA Y NA Y NA N Y Y Y Y 78 
Barry 
1995 [56] 
Y NA NA NA Y NA Y NA Y NA Y Y Y Y Y 90 
Basra 
2006 [74] 
Y NA NA NA N NA Y NA Y NA Y Y Y Y N 78 
El Din 
1999 [63] 
Y NA N NA N NA Y NA Y NA N Y Y Y N 60 
Johnson, 
2009 [55] 
Y NA Y NA N NA Y NA Y NA Y Y Y Y Y 90 
O’Connor 
2003 [60] 
Y NA NA NA N NA Y NA Y NA Y Y N Y N 67 
Cam, 2004 
[52] 
Y NA N NA Y NA Y NA Y NA Y Y Y Y N 80 







Y NA NA NA N NA Y NA Y NA Y Y Y Y Y 90 
Rotar, 
2009 [66] 
Y NA Y NA N NA Y NA Y NA Y Y Y Y Y 90 
Badia, 
1998 [62] 
Y NA NA NA N NA Y NA Y NA N Y Y Y Y 78 
Gotoh, 
2009 [65] 
Y NA NA NA N NA Y NA Y NA N Y Y Y N 67 
Hammad 
2010 [57] 
Y NA NA NA N NA Y NA Y NA Y Y Y Y N 78 
Quek 2005 
[59] 
Y NA NA NA N NA Y NA Y NA N Y Y Y Y 78 
Tubaro 
2006 [68] 























































































                 

























Y Y NA NA NA Y NA Y Y Y Y Y Y Y N 91 
Sahai 2014 
[73] 
Y Y NA NA NA Y NA Y Y Y Y Y Y Y Y 100 
Okamura, 
2009 [58] 
Y NA NA NA NA NA NA NA Y NA Y Y Y Y Y 100 
Rotar, 
2009 [66] 
Y Y NA NA NA Y NA Y Y Y Y Y Y Y Y 100 
Badia, 
1998 [62] 
NA Y NA NA NA Y NA Y Y Y N Y Y Y Y 90 
Gotoh, 
2009 [65] 
Y Y NA NA NA Y NA Y Y Y N Y Y Y N 82 
Hammad 
2010 [57] 
Y N NA NA NA Y NA Y Y Y Y Y Y Y N 82 
Tubaro 
2006 [68] 
Y Y NA NA NA Y NA Y Y Y Y Y Y Y N 91 
Hashim 
2006 675] 




Y Y Y NA NA Y NA Y Y Y N Y Y Y N 83 
Question1= Did the authors give a detailed description of the sample of subjects used to perform the (index) test?; Question 2 = Was the reference standard explained?; Question 3 =  If inter-rater 
reliability was tested, were raters blinded to the findings of other raters?; Question 4 = If intra-rater reliability was tested, were raters blinded to their own prior findings of the test under evaluation?; 
Question 5 = Was the order of the questions/tests varied?; Question 6 = Was the time period between the reference standard and the index test short enough to be reasonably sure that the target condition 
did not change between the two tests?; Question 7 = Was the stability (or theoretical stability) of the variable being measured taken into account when determining the suitability of the time interval 
between repeated measures?; Question 8 = Was the reference standard independent of the index test?; Question 9 = Was the execution of the (index) test described in sufficient detail to permit replication 
of the test?; Question 10 = Was the execution of the reference standard described in sufficient detail to permit its replication?; Question 11 = Were withdrawals from the study explained?; Question 12 = 
Were the statistical methods appropriate for the purpose of the study? Question 13 = Were subjects selected either randomly or consecutively? Question 14 = Was the number of subjects either >50 or was 
a sample size calculation provided?; Question 15 = Did subjects give consent prior to testing/participating?; r = reliability; v = validity; NA = not applicable.   
 
 
 
